TransMedics Group, Inc.
TMDX$2.72B
Mid CapNASDAQElectromedical & Electrotherapeutic Apparatus🇺🇸North AmericaANDOVER728 employees
Drugs in Pipeline
0
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
TMDX News
Catalyst Timeline
1 upcoming, 0 past
EarningsNext
TMDX Earnings Report
Aug 4, 2026Confirmed
EPS Est: $0.50 | FQ end 2026-06 | Call: 2026-08-04 15:00:00
How TMDX's past catalysts played out
Drug Pipeline
No drugs found in this phase.
📑
→Catalyst DossierPRO
The full research note — thesis, the if-approved scenario, financials & smart money. Compiled by CeliA.
Catalyst Verdict
Full breakdown — the signals behind the verdict
Market-Implied Move
Regulatory Approvals
Frequently asked questions
When is TransMedics Group, Inc.'s next FDA catalyst?→
TransMedics Group, Inc.'s (TMDX) next tracked catalyst is a Earnings expected August 4, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track TMDX biotech catalysts?→
Add TMDX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow TransMedics Group, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply